At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 197 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)
In Brief
A Phase 4 clinical trial evaluating Nivolumab for Renal Cell Carcinoma. Completed, enrolled 197 participants across 39 sites.
Detailed Summary
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated adverse events (IMAEs), in patients treated with Nivolumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJan 2016
Primary CompletionMar 2018
Study CompletionMay 2021
TodayJul 2026
First PostedNov 4, 2015
Enrollment StartJan 8, 2016
Primary CompletionMar 19, 2018
Study CompletionMay 24, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.7 years ago
Interventions
Nivolumabdrug